Empowering Potent Therapeutic Cell Lines with Superior Tumor Targeting Mechanisms
Acepodia has designed enhanced cell therapy approaches that are differentiated with bolstered potency for enhanced tumor-killing. The company's next-generation therapies are based on proprietary immune cells combined with both novel and well-established targeting mechanisms through Antibody-Cell Conjugation (ACC) technology.
oNK cells are a unique off-the-shelf natural killer cell line, with potent anticancer activity, ideally suited for application of tumor-targeting machinery, such as through ACC or CAR technology.
ACC technology is a new approach to cell therapy development that attaches tumor-targeting antibodies directly to the surface of immune cells to enhance and direct their anticancer activity. Acepodia is applying this technology to its oNK cells and γδ T cells.
γδ T cells are an off-the-shelf cell line that can directly target cancer cells as well as recruit the immune system to elicit a robust anticancer response.